✦ LIBER ✦

Priming of NADPH oxidase by tumor necrosis factor alpha in patients with inflammatory and autoimmune rheumatic diseases

✍ Scribed by Ralf Miesel; Robert Hartung; Hans Kroeger

Publisher: Springer
Year: 1996
Tongue: English
Weight: 602 KB
Volume: 20
Category: Article
ISSN: 0360-3997
DOI: 10.1007/bf01486744

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Elevated levels of xanthine oxidase in s

Elevated levels of xanthine oxidase in serum of patients with inflammatory and autoimmune rheumatic diseases

✍ Ralf Miesel; Margit Zuber 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 660 KB

Increased levels of soluble tumor necros

Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases

✍ Andrew P. Cope; Deena Gibbons; Fionula M. Brennan; Marc Feldmann; Dan Aderka; Mi 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 815 KB

AUF1, the regulator of tumor necrosis fa

AUF1, the regulator of tumor necrosis factor α messenger RNA decay, is targeted by autoantibodies of patients with systemic rheumatic diseases

✍ Karl Skriner; Wolfgang Hueber; Erhan Süleymanoglu; Elisabeth Höfler; Veit Krenn; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 512 KB

Presentation and outcome of histoplasmos

Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: A case series

✍ Jennifer L. Dotson; Wallace Crandall; Hayat Mousa; Jonathan R. Honegger; Lee Den 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB 👁 1 views

Background: Antitumor necrosis factor alpha (aTNF) therapies are commonly used in the treatment of pediatric inflammatory bowel disease (IBD). However, inhibition of the TNF-alpha pathway predisposes to serious infections, including histoplasmosis, which is the most common invasive fungal infection

Suppression of interleukin-1β- and tumor

Suppression of interleukin-1β- and tumor necrosis factor-·-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis

✍ Akira Andoh; Atsuhiro Ogawa; Ken-ichi Kitamura; Osamu Inatomi; Sanae Fujino; Tom 📂 Article 📅 2004 🏛 Springer Japan 🌐 English ⚖ 322 KB

Differences in the incidence of flares o

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents

✍ Braun, J. ;Baraliakos, X. ;Listing, J. ;Davis, J. ;van der Heijde, D. ;Haibel, H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## Objective Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically and pathologically linked. Anti–tumor necrosis factor (anti‐TNF) agents are efficacious in treating AS, but not all are equally effective in treating IBD (Crohn's disease [CD] and ulcerative co